Search

Your search keyword '"Izuzquiza M"' showing total 4 results
Start Over Author "Izuzquiza M" Journal hematological oncology
4 results on '"Izuzquiza M"'

1. FACTORS INFLUENCING SURVIVAL AND PROLONGED VIRAL REPLICATION IN PATIENTS WITH LYMPHOMA AND COVID‐19: AN OBSERVATIONAL COHORT STUDY FROM GELTAMO SPANISH GROUP

Author

Cabero‐Martínez, A., primary, Bastos‐Oreiro, M., additional, López‐García, A., additional, Baile, M., additional, Franch, M., additional, Llacer‐Ferrandis, M. J., additional, Izuzquiza, M., additional, Jiménez‐Ubieto, A., additional, Escoda, L., additional, Nistal, S., additional, González‐Barca, E., additional, García‐Belmonte, D., additional, Hernández‐Mohedo, F., additional, Sánchez‐González, B., additional, Martin‐Martitegui, X., additional, Arguiñano, J. M., additional, Ramirez‐Payer, A., additional, Roldan‐Perez, A., additional, Zeberio, I., additional, Diaz‐Galvez, J., additional, Cannata‐Ortiz, J., additional, Peñarrubia, M. J., additional, Campo, R. del, additional, Luzardo, H., additional, Solé‐Rodríguez, M., additional, Lorente, S., additional, Muntañola, A., additional, Alonso‐Prieto, C., additional, Yamil, G., additional, Villafuerte, P., additional, Guillen‐Garcia, H., additional, Gómez‐Roncero, M. I., additional, Infante, M. S., additional, Peñalver, F. J., additional, Cortés, M., additional, Abrisqueta, P., additional, Córdoba, R., additional, Sancho, J. M., additional, and García‐Sancho, A. Martin, additional

Published
2023
Full Text
View/download PDF

2. A phase II, open‐label, multicenter study of capivasertib, a potent, oral pan‐AKT inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma (CAPITAL)

Author

Hodson, D., primary, Shouse, G., additional, Shin, H., additional, Salar, A., additional, Bobillo, S., additional, Ribrag, V., additional, Macpherson, N., additional, Cordoba, R., additional, Kim, J. S., additional, Radford, J., additional, Guidez, S., additional, Herrera, A. F., additional, Morchhauser, F., additional, Johnson, D., additional, Izuzquiza, M., additional, Sambamurthy, N., additional, Forcina, A., additional, Gorgun, G., additional, Chen, R., additional, Younes, A., additional, Wang, M., additional, and Kim, W. S., additional

Published
2023
Full Text
View/download PDF

3. OUTCOMES OF PATIENTS WITH LYMPHOMA AND COVID‐19: AN OBSERVATIONAL COHORT STUDY FROM GELTAMO SPANISH GROUP

Author

García‐Sancho, A. Martín, primary, Izuzquiza, M., additional, Bastos‐Oreiro, M., additional, Baile, M., additional, Nistal, S., additional, Cortés, M., additional, Jiménez‐Ubieto, A., additional, Búa, B. Rey, additional, Guillén‐García, H., additional, Cannata‐Ortiz, J., additional, Novelli, S., additional, Gómez‐Roncero, M. I., additional, Peñalver, F. J., additional, Barca, E. M. González, additional, Infante, M., additional, Peñarrubia, M. Jesús, additional, Franch, M., additional, Alonso‐Prieto, C., additional, Zeberio, I., additional, Sánchez‐González, B., additional, Muntañola, A., additional, Hernández‐Mohedo, F., additional, Martín‐Martitegui, X., additional, Arguiñano, J. María, additional, Campo, R. del, additional, Escoda, L., additional, Roldán‐Pérez, A., additional, Ramírez‐Payer, Á., additional, Luzardo, H., additional, Lorente, S., additional, Solé‐Rodríguez, M., additional, Abrisqueta, P., additional, and Sancho, J. M., additional

Published
2021
Full Text
View/download PDF

4. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry.

Author

Musto P, Salmanton-García J, Sgherza N, Bergantim R, Farina F, Glenthøj A, Cengiz Seval G, Weinbergerová B, Bonuomo V, Bilgin YM, van Doesum J, Jaksic O, Víšek B, Falces-Romero I, Marchetti M, Dávila-Valls J, Martín-Pérez S, Nucci M, López-García A, Itri F, Buquicchio C, Verga L, Piukovics K, Navrátil M, Collins GP, Jiménez M, Fracchiolla NS, Labrador J, Prezioso L, Rossi E, Čolović N, Meers S, Kulasekararaj A, Cuccaro A, Blennow O, Valković T, Sili U, Ledoux MP, Batinić J, Passamonti F, Machado M, Duarte RF, Poulsen CB, Méndez GA, Espigado I, Demirkan F, Čerňan M, Cattaneo C, Petzer V, Magliano G, Garcia-Vidal C, El-Ashwah S, Gomes-Da-Silva M, Vena A, Ormazabal-Vélez I, van Praet J, Dargenio M, De-Ramón C, Del Principe MI, Marques-De-Almeida J, Wolf D, Szotkowski T, Obr A, Çolak GM, Nordlander A, Izuzquiza M, Cabirta A, Zambrotta GPM, Cordoba R, Žák P, Ammatuna E, Mayer J, Ilhan O, García-Sanz R, Quattrone M, Arellano E, Nunes-Rodrigues R, Emarah Z, Aiello TF, Hanakova M, Ráčil Z, Bavastro M, Limongelli A, Rahimli L, Marchesi F, Cornely OA, and Pagano L

Subjects
Humans, SARS-CoV-2, Pandemics, Registries, COVID-19, Multiple Myeloma therapy
Abstract

Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 10 9 /L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic., (© 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results